Cambridge Nutritional Sciences PLC Notice of Results and Investor Presentation

RNS Number : 4304M

Cambridge Nutritional Sciences PLC

15 November 2024

 

15 November 2024

 

Cambridge Nutritional Sciences plc

 

(the "Company" or "CNSL")

 

Notice of Results and Investor Presentation

 

Cambridge Nutritional Sciences plc (AIM:CNSL), the specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition, confirms it will issue its Half Year results for the six months ended 30 September 2023 on Thursday 21 November 2024.

 

Investor presentation

There will be a live presentation relating to the Half Year Results via the Investor Meet Company platform on Thursday 21 November 2024 at 16:00 GMT.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 20 Nov 2024, 09:00 GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Cambridge Nutritional Sciences plc via:

 

https://www.investormeetcompany.com/cambridge-nutritional-sciences-plc/register-investor

 

Investors who already follow Cambridge Nutritional Sciences plc on the Investor Meet Company platform will automatically be invited.

 

 

 

Contacts: 

Cambridge Nutritional Sciences plc	www.cnsplc.com
Carolyn Rand, Executive Chair	[e-mail]
James Cooper, Interim Chief Executive
Cavendish Capital Markets Limited	Tel: [phone]
Geoff Nash / Edward Whiley / (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical diagnostics company focused on promoting a personalised and functional approach to health and nutrition.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

NORFFDSUIELSEEF